Posted by on February 7, 2011 - 5:46pm

Women with peripheral artery disease (PAD)  lose ability to walk short distances and climb stairs sooner than men.

Peripheral arterial disease occurs when plaque  builds up in the arteries that carry blood to your head, organs, and limbs. Plaque is made up of fat, cholesterol, calcium, fibrous tissue, and other substances in the blood.When plaque builds up in arteries, the condition is called atherosclerosis. Over time, plaque can harden and narrow the arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body.  PAD usually affects the legs, but also can affect the arteries that carry blood from your heart to your head, arms, kidneys, and stomach. This article focuses on PAD that blocks arteries going to or in the legs.

Small calf muscles may be a feminine trait, but for women with PAD they’re a major disadvantage. Researchers at Northwestern Medicine point to the smaller calf muscles of women as a gender difference that may cause women with PAD to experience problems walking and climbing stairs sooner and faster than men with the disease.   The study was published in the February 2011 issue of the Journal of the American College of Cardiology.

Peripheral artery disease affects eight million men and women in the United States. The disease causes blockages in leg arteries, and patients with PAD are at an increased risk of having a heart attack or stroke, said Mary McDermott, M.D., professor of medicine and of preventive medicine at Northwestern University Feinberg School of Medicine and physician at Northwestern Memorial Hospital.

McDermott and a team of researchers observed 380 men and women with PAD for four years, measuring their calf muscle characteristics and leg strength every year. Oxygen is needed to fuel calf muscles, and blockages in leg arteries prevent oxygen from reaching the calf muscles of people with PAD.

The researchers also tracked whether or not the patients could walk for six minutes without stopping and climb up and down a flight of stairs without assistance every year.

“After four years, women with PAD were more likely to become unable to walk for six minutes continuously and more likely to develop a mobility disability compared to men with the disease,” said McDermott, lead author of the study. “When we took into account that the women had less calf muscle than men at the beginning of the study, that seemed to explain at least some of the gender difference.”

Interestingly, men in this study experienced a greater loss of calf muscle annually than the women. But the men had more lower extremity muscle reserve than the women. That may have protected men against the more rapid functional decline women experienced.   “We know that supervised treadmill exercise can prevent decline, so it’s especially important for women with PAD to get the diagnosis and engage in walking exercise to try and protect against decline,” McDermott said.

Source:   Erin White, Northwestern NewCenter

Posted by on February 6, 2011 - 3:45pm

In celebration of  Women's Heart Month, the Institute for Women's Health Research featured heart disease in women in its February E-newsletter.    To view this free newsletter, click Heart Disease in Women Enewsletter.

Posted by on February 3, 2011 - 10:24am

Women taking a low dose of the antidepressant escitalopram had fewer and less severe hot flashes than those taking a placebo, a new clinical trial reports.

Menopause is a transition that affects many women as they approach age 50. It marks the end of menstrual periods and fertility. It can also bring hot flashes, trouble sleeping, mood changes and other symptoms.

Menopausal hormone therapy has long been the predominant treatment for menopausal symptoms. However, its use has greatly declined since 2002, when a large NIH-funded study concluded that the overall risks of menopausal hormone therapy likely outweigh the benefits in certain groups of women.

No other treatments for menopausal hot flashes currently have FDA approval. Recent studies suggest that certain anti-depressant medications may be effective for relieving hot flashes, but the results have been inconclusive.

Dr. Ellen W. Freeman at the University of Pennsylvania School of Medicine and her colleagues enrolled over 200 healthy menopausal or postmenopausal women. The women were given either a daily dose of escitalopram or a placebo for 8 weeks. The researchers tracked the number, severity and irritation of their hot flashes. The trial was funded by NIH’s National Institute on Aging (NIA) and several other NIH components.

As described in the January 19, 2011, issue of the Journal of the American Medical Association the researchers found that women taking escitalopram had an average of nearly 50% fewer hot flashes after 4 weeks. In comparison, women taking the placebo had on average of 26% fewer hot flashes. The escitalopram treatment led to even further reductions in hot flashes after 8 weeks. Women taking the medication also reported a reduction in the severity and bother of their hot flashes.

An equal number of white and African American women participated in the study. Race had no significant effect on the treatment results.

While it is not clear exactly why antidepressants like escitalopram are effective for treating hot flashes, the study shows that these drugs could be a safe alternative to hormone therapy. Women taking escitalopram reported few adverse side effects during or after the clinical trial. Furthermore, a majority of the women said they were satisfied with the treatment and would like to continue taking escitalopram.

"Our findings suggest that among healthy women who were not depressed or anxious, a 10 to 20 milligram dose of escitalopram provides a non-hormonal, off-label option that is effective and well-tolerated in the management of menopausal hot flashes," Freeman says.

Source:   National Institutes of Health

Posted by on February 1, 2011 - 12:05pm

Due to the blizzard expected in Chicago today,  Hot Flash Havoc ---a film of menopausal proportions, will be rescheduled at Northwestern University and be shown on Thursday night, February 3.    The award winning film will be followed by a panel of experts from Northwestern who will be available to answer all your questions about menopause.     To register for the event, click HERE and go to  ' buy tickets'  $25 includes the film, parking, panel discussion and red boa reception!

Posted by on January 31, 2011 - 6:52pm

The safety and comfort level of a popular unstructured boot has recently been in the news.  These slipper-like boots, originally from Australia but copied by many manufacturers, have become the darling of celebrities and the fashion "must have" for women and girls all over the globe.   Podiatrists (foot doctors) have  been issuing warnings about these furry boots, especially if worn for extended periods of time.   One of the most common orthopedic complaints is plantar fasciitis. Plantar fasciitis is the most common cause of heel pain. This condition occurs when the long fibrous plantar fascia ligament along the bottom of the foot develops tears in the tissue resulting in pain and inflammation. Its symptoms include burning, stabbing, or aching pain in the heel of the foot. Most sufferers will be able to feel it in the morning because the fascia ligament tightens up during the night while we sleep, causing pain to diminish. However, when we climb out of bed and place pressure on the ligament, it becomes taut and pain is particularly acute. The pain may decrease when the tissue warms up but it can return with increased activity during the day.

Plantar fasciitis can occur for a variety of reasons.  Among the most common is an overload of physical activity or exercise.  Another common cause of plantar fasciitis is arthritis. Certain types of arthritis can cause inflammation to develop in tendons, resulting in plantar fasciitis. This cause is particularly common among elderly patients. Diabetes is also a factor that can contribute to further heel pain and damage, particularly among the elderly.

Among the most popular causes that contribute to plantar fasciitis is wearing incorrect shoes. In many cases, shoes either do not fit properly, or provide inadequate support or cushioning. While walking or exercising in improper shoes, weight distribution becomes impaired, and significantly stress can be added to the plantar fascia ligament.   The boots mentioned in this blog have little support and have been linked to an increase in plantar fasciitis.

No one  is suggesting that you throw your favorite boots away.  They are comfortable and warm,  but they simply do not provide sufficient  support for extended use.  If you can't live without them and want to wear them daily, consider getting a custom-made orthotic foot mold to put in your boot, or use supportive insoles.    Women with flattened arches are even more prone to foot problems as a result of shoes with ill fitting shoes.

Posted by on January 31, 2011 - 11:03am

Though the risk of gout is low in women, a new study reported in JAMA found that increasing intake of sugar-sweetened soda was associated with an increasing risk of gout.   Women who consumed 1 serving per day (compared to women who had less than 1 serving per month) had a a 74% increased risk of gout.   Women who consumed 2 or more servings had a 2.4 times higher risk.    The same result was not found in women drinking diet soft drinks. However, a single serving of orange juice per day also demonstrated an increased risk.

Fructose rich drinks increase serum uric acid levels, a trigger for gout, though the prospective data on the relationship are limited.

The researchers analyzed 78,906 women with no history of gout from the U.S. Nurses' Health Study.  They identified newly diagnosed cases of gout in 778 of the women.

Gout is a painful inflammatory type of arthritis.   5% of arthritis cases are gout.   In the U.S. 8.5/1000 people have had gout.   Gout affects men more than women.

Posted by on January 27, 2011 - 5:18pm

After an intensive review of known cases of a rare form of cancer in breast implant recipients, the Food and Drug Administration says women with implants may have a very small, but increased risk of developing anaplastic large cell lymphoma, or ALCL.

FDA scientists reached that conclusion after examining scientific literature that focused on cases of ALCL in 34 women with breast implants, as well as information from agency reports, international regulatory agencies, scientific experts, and breast implant manufacturers.

But with an estimated five to 10 million breast implant recipients worldwide, agency experts say the known ALCL cases are too few to say conclusively that breast implants cause the disease. FDA believes there are about 60 of these ALCL cases worldwide, though that number is difficult to verify because not all of them were chronicled in scientific publications and some reports may have been duplicated.

In an effort to gather more information, FDA and the American Society of Plastic Surgeons are establishing a registry of ALCL patients who have breast implants. FDA scientists hope the registry yields enough information to better understand what the risks for developing ALCL are for women with breast implants.

The Institute for Women's Health Research at Northwestern University encourages women to participate in the registry that is being set up so that researchers will be able to confirm whether there is a statistically significant risk.  More studies are needed and this registry will provide a tool that will be very valuable.   To read the full FDA advisory, click HERE.

Posted by on January 26, 2011 - 1:15pm
A new drug delivery technique may hold promise for more efficient cancer therapies. The technique involves storing a cancer drug inside tiny objects called nanoparticles which can carry drug molecules and target them to specific cells.  Using this method, researchers were able to shrink tumors in mice while using smaller doses of the drug to reduce harmful side effects.  For example, the chemotherapy drug cisplatin is an effective cell killer. It's used against half of all human cancers. However, cisplatin carries serious side effects, like kidney and nerve damage. These side effects limit the dose that can be used, which is a problem because the drug only lasts in the bloodstream for a short time.

Recently, a team of scientists from the Massachusetts Institute of Technology and Brigham and Women's Hospital showed that they could store an inactive form of cisplatin, called a prodrug, inside nanoparticles that are engineered to target a specific protein on prostate cancer cells. Once the cells take up the nanoparticle, the prodrug is released and converted to its active form. The team showed that these drug-carrying particles kill cancer cells in culture more efficiently than the drug alone.

Further work will be needed to show whether this technique works as well in humans as it does in small animals. If so, the targeted delivery of drugs using nanoparticles could become an exciting step into the future of cancer therapy.  This work was published in the January 10, 2011 issue of the Proceedings of the National Academy of Sciences.

Posted by on January 24, 2011 - 2:51pm

Hot Flash Havoc, a film on menopause, will be presented on February 2, 2011 in Chicago.  A panel of experts and a reception follow the film.  Click HERE.for information.

Pages